• Profile
Close

Herpes zoster, hepatitis C, and tuberculosis risk with apremilast compared to biologics, DMARDs and corticosteroids to treat psoriasis and psoriatic arthritis

Clinical Epidemiology Feb 14, 2020

Hagberg KW, Persson R, Vasilakis-Scaramozza C, et al. - In this cohort study of individuals with treated psoriasis or psoriatic arthritis (PsA), researchers applied MarketScan (2014– 2018) to determine rates of herpes zoster, hepatitis C (HepC) and tuberculosis (TB) with apremilast matched to other systemic treatments. A total of 131,604 individuals were recruited in this study. After March 21, 2014, individuals were exposed from first apremilast [APR], DMARD, TNF-inhibitor [TNF], IL-inhibitor [IL], or corticosteroids [CS] prescription. This study estimated incidence rates (IRs) [95% confidence intervals] per 1000 patient-years. The study found variations in rates of herpes zoster after the treatment: highest among those who received polytherapy, lowest in users of apremilast only. For all exposures, IRs for HepC and TB were low.
Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay